Skip to Content

Vimpat Approval History

FDA Approved: Yes (First approved October 28, 2008)
Brand name: Vimpat
Generic name: lacosamide
Dosage form: Tablets and Injection
Company: UCB
Treatment for: Seizures

Vimpat (lacosamide) is an anti-convulsant drug for the treatment of partial onset seizures in adults with epilepsy.

Development History and FDA Approval Process for Vimpat

DateArticle
Oct 29, 2008Approval UCB's Vimpat Approved By U.S. FDA As Adjunctive Therapy for Partial Onset Seizures in Adults
Jul 29, 2008UCB Receives Not-Approvable Letter from FDA for Lacosamide for Diabetic Neuropathic Pain
Nov 29, 2007UCB Announces FDA Filing for lacosamide in the Treatment of Partial Onset Seizures in Adults with Epilepsy
Nov 28, 2007UCB Announces FDA Filing for lacosamide in the Treatment of Diabetic Neuropathic Pain

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide